Bruker Posts 14 Percent Jump in Q4 Revenues; MALDI Biotyper Could Receive FDA Approval This Year | GenomeWeb

This story originally ran on Feb 22.

Bruker this week reported fourth quarter 2011 revenues of $475.1 million, up 14 percent from $416.1 million a year ago and beating Wall Street estimates of $468.6 million.

The company posted a profit for the quarter of $39.1 million, or $.23 per share, compared to $29.3 million or $.18 per share a year ago. On a non-GAAP basis, EPS was $.31, beating analyst expectations of $.29 per share.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.